Denali Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
DNLI Nasdaq 2830 www.denalitherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Denali Therapeutics Inc.

Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report? - Jun 5th, 2025 9:30 am
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth - May 8th, 2025 5:37 am
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome - May 6th, 2025 2:01 pm
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - May 5th, 2025 7:13 am
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up - Apr 3rd, 2025 7:32 am
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program - Apr 2nd, 2025 6:00 am
Why You Shouldn't Bet Against Denali (DNLI) Stock - Mar 20th, 2025 6:57 am
Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer - Mar 4th, 2025 6:00 am
Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025? - Mar 3rd, 2025 10:49 am
Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus - Feb 28th, 2025 11:14 am
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - Feb 27th, 2025 2:01 pm
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study - Feb 7th, 2025 7:54 am
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa - Feb 6th, 2025 9:42 am
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™ - Jan 30th, 2025 6:00 am
Denali Gains 26.6% in a Year: How Should You Play the Stock? - Jan 21st, 2025 4:13 am
Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential - Jan 17th, 2025 9:18 am
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases - Jan 13th, 2025 6:00 am
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation - Jan 9th, 2025 9:20 am
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) - Jan 8th, 2025 6:00 am
Denali Therapeutics price target lowered to $32 from $35 at BTIG - Jan 8th, 2025 5:25 am